Clinical Trial Update: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II trial evaluating the safety and efficacy of HLX208 plus HLX10 in non-small cell lung cancer with BRAF V600E mutation, currently with unknown statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLX10
• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN